NOKOMIS, Fla. -- (BUSINESS WIRE) -- As Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D) work to spread the word about the revolutionary magnetic Bio-Assembler, the innovative new technology’s profile received a boost recently when it was featured alongside other exciting breakthroughs in the Nature.com marketplace.
The Bio-Assembler was profiled with recently released cell and tissue culture technologies in a product focus article last month. The ground-breaking device magnetically manipulates cells to form 3-D structures when a solution of biocompatible nanoparticles is added to cells, allowing them to levitate when a magnet is placed on top of the cell culture plate.
The Bio-Assembler’s 96-well format allows for higher throughput toxicology and drug discovery assays, in addition to many other research applications.
The online feature is only the latest bout of positive publicity for the Bio-Assembler. The preeminent review journal Nature Reviews Cancer recently published a review written by n3D co-founder Dr. Glauco Souza and science advisor Dr. Jeanne L. Becker detailing the cell culture levitation system.
The continuing coverage will be a major asset in the RBCC’s mission to spread the word about the Bio-Assembler. The company formed a joint venture with n3D to market and develop the Bio-Assembler last year.
Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.